Food and Drug Administration officials are taking steps to announce a plan for how to regulate cannabis-derived products like CBD and delta-8 THC in the coming months. This comes as the agency is also leading a review into marijuana’s scheduling status.
In interviews with the Wall Street Journal, FDA Principal Deputy Commissioner Janet Woodcock and two other officials steering the agency’s cannabis policy, Patrick Cournoyer and Norman Birenbaum, discussed next steps.
“Given what we know about the safety of CBD so far, it raises concerns for FDA about whether these existing regulatory pathways for food and dietary supplements are appropriate for this substance,” Woodcock said.
The FDA officials said that a couple of points they are assessing concern whether CBD can be used safely in the long-term, and what impacts consumption might have during pregnancy. The rise in popularity of delta-8 THC products, which the Drug Enforcement Administration (DEA) says are not controlled substances, has further complicated rulemaking.
FDA’s recommendations won’t be binding, but officials expect the United States Drug Enforcement Administration (DEA) to produce a scheduling recommendation that’s consistent with their findings regarding risks and benefits.
Read more at Tinyurl.com/hqnews-review
